Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy
Strong Results But Merck & Co’s Keytruda Also Competing
Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.
You may also be interested in...
Twin Presentations Position Merck, GSK PD-1 Inhibitors As Endometrial Cancer Rivals
Merck’s Keytruda may nevertheless have the stronger market position given its broader and stronger labeling in second-line endometrial cancer and strong position in women’s oncology overall.
Pfizer Returns Bavencio Rights To Merck KGaA, Closing An IO Era
The arrangement ends a nearly 10-year collaboration between Pfizer and Merk KGaA on the PD-L1 inhibitor that, despite some success, never reached its ultimate goal.
Another New Home For Momelotinib As GSK Buys Sierra
GlaxoSmithKline is paying a 39% premium to buy Sierra Oncology and its myelofibrosis therapy momelotinib which is set to be filed shortly in the US on the back of a strong Phase III package.